-
公开(公告)号：US20230271946A1
公开(公告)日：2023-08-31
申请号：US18134564
申请日：2023-04-13
Applicant: Bristol-Myers Squibb Company
Inventor： Ke Chen , Joerg Deerberg , Dong Lin , Michael Dummeldinger , Bahar Inankur , Sergei Kolotuchin , Jun Li , Amanda J. Rogers , Victor W. Rosso , Eric M. Simmons , Maxime C.D. Soumeillant , Daniel S. Treitler , Jianji Wang , Bin Zheng , Michael J. Smith , Neil A. Strotman , Steven Tymonko , Tamas Benkovics
IPC: C07D403/12 , C07C211/09 , C07D237/24 , C07D249/08
CPC classification number: C07D403/12 , C07C211/09 , C07D237/24 , C07D249/08 , C07B2200/13
Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula:
Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.-
![Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof](/abs-image/US/2015/11/03/US09173879B2/abs.jpg.150x150.jpg)
2.发明授权Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof 有权（S）-7 - （[1,2,4]三唑并[1,5-a]吡啶-6-基）-4-（3,4-二氯苯基）-1,2,3,4-四氢异喹啉的结晶形式 四氢异喹啉及其用途公开(公告)号：US09173879B2
公开(公告)日：2015-11-03
申请号：US14466009
申请日：2014-08-22
Applicant: Bristol-Myers Squibb Company
Inventor： Chenkou Wei , Victor W. Rosso , Qi Gao
IPC: C07D471/04 , A61K31/495 , A61K31/4725 , A61K31/437 , A61K31/438 , A61K45/06
CPC classification number: A61K31/4725 , A61K31/437 , A61K31/438 , A61K31/495 , A61K45/06 , C07D471/04
Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
Abstract translation: 在本发明中描述了新的[1,2,4]三唑并[1,5-a]吡啶基-6-基取代的四氢异喹啉。 这些化合物和结晶形式SA1和N-2用于治疗各种神经和生理疾病。 制备这些化合物和结晶形式SA-1和N-2的方法也在本发明中描述。
-
![CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF](/abs-image/US/2014/12/11/US20140364441A1/abs.jpg.150x150.jpg)
3.发明申请CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF 有权（S）-7 - （[1,2,4]三唑并[1,5-a]吡啶-6-基）-4-（3,4-二氯苯基）-1,2,3,4-四氢异喹啉的晶体形式 四氢喹诺酮及其用途公开(公告)号：US20140364441A1
公开(公告)日：2014-12-11
申请号：US14466009
申请日：2014-08-22
Applicant: Bristol-Myers Squibb Company
Inventor： Chenkou Wei , Victor W. Rosso , Qi Gao
IPC: A61K31/4725 , A61K45/06 , C07D471/04
CPC classification number: A61K31/4725 , A61K31/437 , A61K31/438 , A61K31/495 , A61K45/06 , C07D471/04
Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
Abstract translation: 在本发明中描述了新的[1,2,4]三唑并[1,5-a]吡啶基-6-基取代的四氢异喹啉。 这些化合物和结晶形式SA1和N-2用于治疗各种神经和生理疾病。 制备这些化合物和结晶形式SA-1和N-2的方法也在本发明中描述。
-
Patent Agency Ranking
公开(公告)号：US12129245B2
公开(公告)日：2024-10-29
申请号：US17587374
申请日：2022-01-28
Applicant: Bristol-Myers Squibb Company
Inventor： Victor W. Rosso
IPC: C07D403/12
CPC classification number: C07D403/12 , C07B2200/13
Abstract: Disclosed is crystalline Form E of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form E is a neat crystalline form. Characterization data for Form E are disclosed.
-
公开(公告)号：US20220259183A1
公开(公告)日：2022-08-18
申请号：US17587374
申请日：2022-01-28
Applicant: Bristol-Myers Squibb Company
Inventor： Victor W. Rosso
IPC: C07D403/12
Abstract: Disclosed is crystalline Form E of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form E is a neat crystalline form. Characterization data for Form E are disclosed.
-
6.发明申请PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS 审中-公开制备用于治疗病毒感染的核苷类化合物的二异氰酸酯衍生物的方法公开(公告)号：US20150183818A1
公开(公告)日：2015-07-02
申请号：US14409523
申请日：2013-07-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Kristy Tran , Martin D. Eastgate , Jacob Janey , Ke Chen , Victor W. Rosso
CPC classification number: C07H19/20 , C07D471/08 , C07F9/2458 , C07F9/26 , C07F9/65586 , C07F9/65616 , C07H19/10 , C07H19/16
Abstract: The present invention is directed to a process for preparing diastereomerically enriched nucleoside phosphoramidates having the formula I:
Abstract translation: 本发明涉及一种制备具有式I的非对映体富集的核苷氨基磷酸酯的方法：
-
公开(公告)号：US20210107897A1
公开(公告)日：2021-04-15
申请号：US17131718
申请日：2020-12-22
Applicant: Bristol-Myers Squibb Company
Inventor： Ke Chen , Joerg Deerberg , Dong Lin , Michael Dummeldinger , Bahar Inankur , Sergei Kolotuchin , Jun Li , Amanda J. Rogers , Victor W. Rosso , Eric M. Simmons , Maxime C.D. Soumeillant , Daniel S. Treitler , Jianji Wang , Bin Zheng , Michael J. Smith , Neil A. Strotman , Steven Tymonko , Tamas Benkovics
IPC: C07D403/12 , C07C211/09 , C07D237/24 , C07D249/08
Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
-
公开(公告)号：US10899745B2
公开(公告)日：2021-01-26
申请号：US16498442
申请日：2018-03-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ke Chen , Joerg Deerberg , Dong Lin , Michael Dummeldinger , Bahar Inankur , Sergei Kolotuchin , Jun Li , Amanda J. Rogers , Victor W. Rosso , Eric M. Simmons , Daniel S. Treitler , Jianji Wang , Michael J. Smith , Tamas Benkovics
IPC: C07D403/12 , C07C211/09 , C07D237/24 , C07D249/08
Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.023 seconds)
